DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Genetic Testing - Global Strategic Business Report" report to their offering.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
This report analyzes the worldwide markets for Genetic Testing in US$ Million.
The US market is further analyzed by the following Segments:
- Prenatal & Newborn Genetic Testing
- Pharmacogenomic Testing
- Predictive Diagnostics.
The report profiles 88 companies including many key and niche players such as:
- 23andMe, Inc. (USA)
- Abbott Laboratories (USA)
- AutoGenomics, Inc. (USA)
- Biocartis NV (Belgium)
- BioRad Laboratories (USA)
- Cepheid Inc. (USA)
- ELITech Group S.P.A. (France)
- Illumina, Inc. (USA)
- Laboratory Corporation of America Holdings (USA)
- Sequenom, Inc. (USA)
- Luminex Corporation (USA)
- Natera, Inc. (USA)
- PerkinElmer, Inc. (USA)
- QIAGEN N.V. (The Netherlands)
- Quest Diagnostics, Inc. (USA)
- Roche Diagnostics Corp. (Switzerland)
- Roche Molecular Diagnostics, Inc. (USA)
- Thermo Fisher Scientific (USA)
- Transgenomic, Inc. (USA)
Key Topics Covered:
1. Global Market Overview
2. Segmental Review
3. Market Trends
4. Molecular Diagnostics Market
5. Product Overview
6. Product Launches/Innovations
7. Recent Industry Activity
8. Focus On Select Players
9. Global Market Perspective
Total Companies Profiled: 88 (including Divisions/Subsidiaries 97)
- The United States (60)
- Canada (5)
- Japan (1)
- Europe (23)
- - France (2)
- - Germany (3)
- - The United Kingdom (2)
- - Spain (1)
- - Rest of Europe (15)
- Asia-Pacific (Excluding Japan) (5)
- Middle East (2)
- Africa (1)
For more information about this report visit https://www.researchandmarkets.com/research/2232vh/genetic_testing